Skip to main content
Clinical Trials/NCT04548739
NCT04548739
Completed
Not Applicable

Cerebral Autoregulation in Pediatric ECMO (ECMOX 2) : Autoregul ECMO - ECMOX2

Nantes University Hospital4 sites in 2 countries132 target enrollmentOctober 22, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Sponsor
Nantes University Hospital
Enrollment
132
Locations
4
Primary Endpoint
Association between CA metrics and neurological outcome
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Children supported by Extra-Corporeal Membrane Oxygenation (ECMO) present a high risk of neurological complications and cerebral autoregulation (CA) impairment may be a risk factor. The first objective is to investigate the association between CA impairments and neurological outcome assessed by the onset of an ANE. The secondary objective is to study the underlying mechanisms influencing CA.

Detailed Description

Patients : All children treated by ECMO in the 4 PICUs involved in the study Measurements : A correlation coefficient between the variations of regional cerebral oxygen saturation (rScO2) as a surrogate of cerebral blood flow and the variations of arterial blood pressure (ABP) is calculated as an index of autoregulation (cerebral oxygenation index (COx), ICM+ software®). CA is monitored either on left (COxl) or both sides. A COx \> 0.3 is considered as critical. Neurological outcome is assessed by the onset of an acute neurologic event (ANE) during the ECMO run.

Registry
clinicaltrials.gov
Start Date
October 22, 2020
End Date
October 16, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Association between CA metrics and neurological outcome

Time Frame: 1 year

Association between the percentage of time spent in critical region of CA and the onset of an acute neurological event (stroke and/or seizures and/or brain death) or not.

Secondary Outcomes

  • Analysis of the influence of PCO2 on CA(1 year)

Study Sites (4)

Loading locations...

Similar Trials